Kamada Ltd
NASDAQ:KMDA
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
4.65
6.42
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Kamada Ltd
Kamada Ltd
Cash from Operating Activities
Kamada Ltd
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Cash from Operating Activities
$41.6m
|
CAGR 3-Years
67%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
Collplant Biotechnologies Ltd
NASDAQ:CLGN
|
Cash from Operating Activities
-$2.8m
|
CAGR 3-Years
15%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Cash from Operating Activities
-$96.1m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Cash from Operating Activities
-$8m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
B
|
Bonus Biogroup Ltd
TASE:BONS
|
Cash from Operating Activities
-₪23.2m
|
CAGR 3-Years
14%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-8%
|
|
|
Pluri Inc
NASDAQ:PLUR
|
Cash from Operating Activities
-$16.2m
|
CAGR 3-Years
22%
|
CAGR 5-Years
10%
|
CAGR 10-Years
1%
|
|
Kamada Ltd
Glance View
Kamada Ltd. engages in the development and production of pharmaceutical products. The firm uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
See Also
What is Kamada Ltd's Cash from Operating Activities?
Cash from Operating Activities
41.6m
USD
Based on the financial report for Sep 30, 2024, Kamada Ltd's Cash from Operating Activities amounts to 41.6m USD.
What is Kamada Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
10%
Over the last year, the Cash from Operating Activities growth was 526%. The average annual Cash from Operating Activities growth rates for Kamada Ltd have been 67% over the past three years , 10% over the past five years .
You don't have any saved screeners yet
